Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

Journal of the American Heart Association, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

The efficacy of icosapent ethyl among patients with very well-controlled baseline low-density lipoprotein cholesterol (LDL-C) is unknown. In this post hoc analysis the REDUCE-IT (Reduction Cardiovascular Events With Icosapent Ethyl-Intervention Trial) randomized clinical trial, statin-treated high cardiovascular risk, elevated triglycerides (135-499 mg/dL), and LDL-C 41 to 100 mg/dL were included. Patients (2 g twice daily) or placebo then stratified by (<55 versus ≥55 mg/dL). primary composite end point included death, nonfatal myocardial infarction, stroke, coronary revascularization, unstable angina. Among 8175 data, 7117 (87.1%) had 1058 (12.9%) <55 mg/dL. mg/dL, rate was lower in group (16.2% 22.8%) than (hazard ratio [HR], 0.66 [95% CI, 0.50-0.87]; absolute risk reduction, 6.6%; P=0.003). a event occurred proportion (17.4% 21.9%) (HR, 0.76 0.69-0.85]; 4.5%; P<0.0001). No significant interaction observed between treatment (P for interaction=0.40). Findings consistent secondary points sensitivity analyses. reduced irrespective LDL-C, including eligible optimal control. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01492361.

Language: Английский

---

Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors

European Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 6, 2024

Abstract Background Maintaining low concentrations of plasma low‐density lipoprotein cholesterol (LDLc) over time decreases the number LDL particles trapped within artery wall, slows progression atherosclerosis and delays age at which mature atherosclerotic plaques develop. This substantially reduces lifetime risk cardiovascular disease (ASCVD) events. In this context, plaque development vulnerability result not only from lipid accumulation but also inflammation. Results Changes in composition immune cells, including macrophages, dendritic T B mast cells neutrophils, along with altered cytokine chemokine release, disrupt equilibrium between inflammation anti‐inflammatory mechanisms sites. Considering that it is a competition LDLc inflammation, instead they are partners crime, present narrative review aims to give an overview main inflammatory molecular pathways linked raised describe impact lipid‐lowering approaches on burden. Although remarkable changes driven by most recent lowering combinations, relative reduction C‐reactive protein appears be independent magnitude lowering. Conclusion Identifying clinical biomarkers (e.g. interleukin‐6) possible targets for therapy holds promise monitoring reducing ASCVD burden suitable patients.

Language: Английский

---

Therapeutic challenges and new therapeutic targets for combined capillary pulmonary hypertension: a review

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: May 2, 2025

With a high frequency and poor prognosis, combined pre-and post-capillary pulmonary hypertension (Cpc-PH) is significant subtype of linked to left-sided heart disease (PH-LHD). The complicated pathophysiology Cpc-PH primarily characterized by elevated venous pressure leading an increase in retrocapillary pressure, which followed artery marked rise vascular resistance (PVR). There currently no well-defined treatment plan for Cpc-PH, there are numerous obstacles overcome. In patients with the effectiveness targeted medications limited debatable. Recent research has revealed that prevalence progression may be influenced genetic factors, metabolic syndrome, oxidative stress, fibrosis. To help doctors better manage treat this review provides detailed description disease’s epidemiology, pathogenesis, diagnostic techniques, current status, potential therapeutic targets.

Language: Английский

---

Emerging Pathways of Action of Eicosapentaenoic Acid (EPA)

JACC Basic to Translational Science, Journal Year: 2025, Volume and Issue: 10(3), P. 396 - 400

Published: March 1, 2025

Language: Английский

---

Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 601 - 601

Published: April 20, 2025

Background: Lipid-lowering therapies are an option for stabilizing lipid levels. Icosapent ethyl (IPE) is a highly purified formulation of eicosapentaenoic acid, which can reduce action, improve plaque stabilization, platelet aggregation, lower TG, and prevent cardiovascular events. IPE frequently used with statins to manage elevated TG However, the evidence on as lipid-lowering agent limited, no updated systematic review meta-analysis have been published considering recent advancements in field newly studies. Therefore, we aim fill this gap. Methods: We PRISMA guidelines PICO (Population, Intervention, Comparison, Outcome) framework conduct review, aiming answer question, “Can benefit patients at risk?” GRADE was evaluate levels adhere highest criteria. Results: Predominantly, evaluated population presented between ≥135 mg/dL 500 LDL-C >40 ≤100 mg/dL. The included studies showed reduction decrease It means that, according our analysis, has effective lowering blood levels, including reducing death events, such non-fatal stroke or hospitalization unstable angina. it worth noting that these results were primarily from undergoing statin therapy. According meta-analysis, may not be considered drug, limited action associated its use evident quantitative results. caution necessary, only two suitable inclusion due differing outcomes analyzed samples. Conclusions: Despite synthesis, possesses anti-inflammatory, anti-thrombotic, anti-atherogenic properties, related protection. Based studies, promising therapy atherosclerotic disease conjunction other therapies, particularly statins, extremely high limitations reviewed include small sample sizes, varying outcomes, duration interventions. Future clinical trials similar intervention durations must designed, meta-analyses following years fully assess effects protector drug.

Language: Английский

---

“A Time to Tear Down and a Time to Mend”: The Role of Eicosanoids in Atherosclerosis

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2024, Volume and Issue: 44(11), P. 2258 - 2263

Published: Oct. 23, 2024

Language: Английский

---